CSTL – Castle Biosciences Inc.
CSTL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
4.78
Margin Of Safety %
Put/Call OI Ratio
0.43
EPS Next Q Diff
-0.31
EPS Last/This Y
-0.47
EPS This/Next Y
0.28
Price
32.01
Target Price
44
Analyst Recom
1.11
Performance Q
66.48
Upside
-171.0%
Beta
0.98
Ticker: CSTL
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | CSTL | 22.97 | 0.23 | 1.00 | 353 |
| 2026-07-14 | CSTL | 23.12 | 0.24 | 999.99 | 355 |
| 2026-07-15 | CSTL | 24.02 | 0.24 | 0.00 | 355 |
| 2026-07-16 | CSTL | 24.22 | 0.24 | 0.00 | 355 |
| 2026-07-17 | CSTL | 24.21 | 0.24 | 999.99 | 355 |
| 2026-07-20 | CSTL | 23.92 | 0.71 | 0.00 | 135 |
| 2026-07-21 | CSTL | 24.52 | 0.73 | 0.00 | 133 |
| 2026-07-22 | CSTL | 24.8 | 0.73 | 0.00 | 133 |
| 2026-07-23 | CSTL | 25.47 | 0.75 | 0.00 | 131 |
| 2026-07-24 | CSTL | 24.7 | 0.75 | 0.00 | 131 |
| 2026-07-27 | CSTL | 24.43 | 0.75 | 0.00 | 131 |
| 2026-07-28 | CSTL | 23.9 | 0.75 | 999.99 | 131 |
| 2026-07-29 | CSTL | 24.48 | 0.76 | 999.99 | 132 |
| 2026-07-30 | CSTL | 26.76 | 0.79 | 0.50 | 134 |
| 2026-07-31 | CSTL | 28.19 | 0.78 | 0.00 | 139 |
| 2026-08-03 | CSTL | 30.43 | 0.21 | 0.13 | 357 |
| 2026-08-04 | CSTL | 31.15 | 0.43 | 5.00 | 431 |
| 2026-08-05 | CSTL | 30.31 | 0.41 | 999.99 | 430 |
| 2026-08-06 | CSTL | 30.47 | 0.43 | 0.00 | 434 |
| 2026-08-07 | CSTL | 31.97 | 0.43 | 0.17 | 435 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | CSTL | 22.98 | -100.0 | -31.8 | -1.40 |
| 2026-07-14 | CSTL | 23.15 | -100.0 | -34.6 | -1.40 |
| 2026-07-15 | CSTL | 23.98 | -100.0 | -36.9 | -1.40 |
| 2026-07-16 | CSTL | 24.24 | -100.0 | -34.8 | -1.40 |
| 2026-07-17 | CSTL | 24.11 | -100.0 | -33.7 | -1.40 |
| 2026-07-20 | CSTL | 23.88 | -100.0 | -33.2 | -1.40 |
| 2026-07-21 | CSTL | 24.52 | -100.0 | -36.0 | -1.40 |
| 2026-07-22 | CSTL | 24.80 | -100.0 | -34.9 | -1.40 |
| 2026-07-23 | CSTL | 25.44 | -100.0 | -35.8 | -1.40 |
| 2026-07-24 | CSTL | 24.69 | -100.0 | -31.9 | -1.42 |
| 2026-07-27 | CSTL | 24.47 | -100.0 | -33.4 | -1.42 |
| 2026-07-28 | CSTL | 23.90 | -100.0 | -32.4 | -1.42 |
| 2026-07-29 | CSTL | 24.45 | -100.0 | -35.9 | -1.42 |
| 2026-07-30 | CSTL | 26.80 | -100.0 | -41.1 | -1.42 |
| 2026-07-31 | CSTL | 28.06 | -100.0 | -37.6 | -1.42 |
| 2026-08-03 | CSTL | 30.35 | -100.0 | -38.6 | -1.42 |
| 2026-08-04 | CSTL | 30.35 | -100.0 | -38.6 | -1.42 |
| 2026-08-05 | CSTL | 30.40 | -100.0 | -23.7 | -1.42 |
| 2026-08-06 | CSTL | 30.48 | -100.0 | -25.3 | -1.42 |
| 2026-08-07 | CSTL | 32.01 | -100.0 | -28.1 | -1.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | CSTL | -21.43 | -1.12 | 5.05 |
| 2026-07-14 | CSTL | -21.69 | -1.12 | 5.05 |
| 2026-07-15 | CSTL | -21.69 | -1.12 | 5.05 |
| 2026-07-16 | CSTL | -21.69 | -1.12 | 5.05 |
| 2026-07-17 | CSTL | -22.01 | -1.12 | 5.05 |
| 2026-07-20 | CSTL | -22.01 | -1.43 | 5.05 |
| 2026-07-21 | CSTL | -22.01 | -1.43 | 5.05 |
| 2026-07-22 | CSTL | -22.15 | -1.43 | 5.05 |
| 2026-07-23 | CSTL | -21.83 | -1.43 | 5.05 |
| 2026-07-24 | CSTL | -21.83 | -1.43 | 5.05 |
| 2026-07-27 | CSTL | -21.83 | -1.32 | 4.81 |
| 2026-07-28 | CSTL | -21.83 | -1.32 | 4.81 |
| 2026-07-29 | CSTL | -21.83 | -1.32 | 4.81 |
| 2026-07-30 | CSTL | -22.60 | -1.32 | 4.81 |
| 2026-07-31 | CSTL | -22.60 | -1.32 | 4.81 |
| 2026-08-03 | CSTL | -22.47 | -0.98 | 4.78 |
| 2026-08-04 | CSTL | -22.47 | -0.98 | 4.78 |
| 2026-08-05 | CSTL | -26.37 | -0.98 | 4.78 |
| 2026-08-06 | CSTL | -29.07 | -0.98 | 4.78 |
| 2026-08-07 | CSTL | -29.07 | -0.98 | 4.78 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.07
Avg. EPS Est. Current Quarter
-0.37
Avg. EPS Est. Next Quarter
-0.38
Insider Transactions
-29.07
Institutional Transactions
-0.98
Beta
0.98
Average Sales Estimate Current Quarter
92
Average Sales Estimate Next Quarter
93
Fair Value
Quality Score
55
Growth Score
43
Sentiment Score
78
Actual DrawDown %
59.3
Max Drawdown 5-Year %
-85
Target Price
44
P/E
Forward P/E
PEG
P/S
2.74
P/B
2.08
P/Free Cash Flow
EPS
-0.65
Average EPS Est. Cur. Y
-1.3
EPS Next Y. (Est.)
-1.02
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-5.43
Relative Volume
0.54
Return on Equity vs Sector %
-31.5
Return on Equity vs Industry %
-15.6
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.1
EBIT Estimation
-28.1
◆
CSTL
Healthcare
$32.03
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
20/20
Pullback
4/25
Volume
11/15
Valuation
10/20
TP/AR
2/10
Options
7/10
RSI
77.4
Range 1M
99.3%
Sup Dist
7.2%
🚀
Momentum Growth
Ride accelerating trends
WEAK
Momentum
16/25
Growth
15/30
Estimates
2/20
Inst/Vol
4/15
Options
9/10
EPS Yr
-53.3%
EPS NY
22.3%
52W%
53.6%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+37.4% upside
Quality
6/30
Valuation
9/30
Growth
12/25
Stability
8/10
LT Trend
4/5
Upside
+37.4%
Quality
55
Click a card to see score breakdown
Full Analysis →
CSTL — P/E HistoricalDiagnostics & Research
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 1002
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
CSTL
Latest News
—
Caricamento notizie per CSTL…
stock quote shares CSTL – Castle Biosciences Inc. Stock Price stock today
news today CSTL – Castle Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CSTL – Castle Biosciences Inc. yahoo finance google finance
stock history CSTL – Castle Biosciences Inc. invest stock market
stock prices CSTL premarket after hours
ticker CSTL fair value insiders trading